Navigation Links
Colorcon Reaffirms World-Wide Patent Positions for Enteric Coating Compositions
Date:3/23/2011

HARLEYSVILLE, Pa., March 23, 2011 /PRNewswire/ -- Colorcon, Inc., a wholly owned subsidiary of BPSI Holdings Inc., today announced specific details on its world-wide patent positions for enteric coating compositions in response to misleading statements made in the international press, particularly in India.  These communications have inaccurately summarized the status of certain patents and patent applications.   Colorcon has more than 15 patents for enteric coatings granted globally for the Acryl-EZE®, aqueous acrylic enteric, and Sureteric®, aqueous enteric systems, including valid patents in India.  These patents remain in full effect.  

"Colorcon will vigorously enforce its patent positions.  We are proud of our strong history of research and development and the resulting innovative products we provide our customers," stated Kamlesh Oza, General Manager for Film Coatings. "Colorcon endeavors to provide best-in-class products and services to the pharmaceutical industry globally.  Our recent customer survey indicates that, above all, the industry values our product range, technical support, and product use guidelines/application data.  Our intellectual property estate enables us to continue investing in the development of advanced products and continually provide the industry with next generation formulated systems with superior overall value."

About Colorcon

Colorcon is a world leader in the development, supply and support of formulated products for the pharmaceutical and nutritional industries. Its core businesses include film coatings, modified release technologies, functional excipients and tablet design services. Colorcon has 18 technical service laboratories globally and more than 1200 employees exclusively dedicated to its customer base.

The patents mentioned herein are owned by BPSI Holdings, Inc.  Colorcon is the exclusive licensee.


'/>"/>
SOURCE Colorcon, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. ARmark Authentication Technologies, LLC and Colorcon, Inc. Announce Alliance
2. Colorcon Acquires Pharmaceutical Excipient Company - NP Pharm
3. Colorcon Acquires Business of Pharmaceutical Coatings Pvt. Ltd. (India)
4. Colorcon Expands Nutraficient Product Portfolio to Include High Productivity, PVA-Based Formulations for Food Supplement Coating
5. Totality of Available Data Reaffirms PROCRIT(R) (Epoetin alfa) Is Safe and Effective When Used Appropriately as Labeled to Treat Chemotherapy-Induced Anemia
6. Huifeng Bio-Pharmaceutical Reported Second Quarter 2010 Financial Results and Reaffirms its 2010 Guidance
7. Mylan Reports Adjusted Diluted EPS of $0.43; Reaffirms 2010 Adjusted Diluted EPS Guidance of $1.55 - $1.65
8. CareFusion Reports First Quarter Fiscal 2011 Results; Reaffirms Fiscal 2011 Financial Guidance
9. Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent
10. Matrixx Initiatives, Inc. Summarizes Ongoing Go-Shop Process and Board Reaffirms Recommendation
11. DSM Obtains Exclusive World-Wide License for Innovative Drug Delivery Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... , Mar. 29, 2017 Research and Markets has ... at Proton Therapy Centers & Forecast" report to their offering. ... Proton Therapy Market in ... its market value in 2016. There are currently three proton therapy centers ... to treat more patients. In Italy , the first ...
(Date:3/29/2017)... 2017  Providence Medical Technology, Inc., an innovator ... two industry veterans to the commercial leadership team.  ... to lead Global Marketing, and Michael Scott ... and Mr. Scott have over 40 years of ... joins the company with over 22 years of ...
(Date:3/29/2017)... 2017  Glenmark Pharmaceuticals, a global pharmaceutical company, ... investigational fixed-dose combination of mometasone furoate (25 mcg) ... a nasal spray being studied for the treatment ... a recently completed Phase 3 trial assessing the ... versus mometasone, olopatadine or placebo. "We ...
Breaking Medicine Technology:
(Date:3/30/2017)... , ... March 30, 2017 , ... ... the live audio conference “ Preventing Hospital Readmissions Through Discharge Planning ” with ... at 1:00 pm ET. This conference discusses strategies to prevent readmissions in light ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... squash, announced it has enlisted New York City-based sports and entertainment marketing firm ... and procure sponsorship opportunities for the Professional Squash Association (PSA), which includes first-time ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sublime Naturals and its founder, Kathy Heshelow, ... Spice", it has been used for thousands of years. , "The West has caught ... of " Turmeric: How to Use it For Your Wellness. Overcome Inflammation, Enemy of ...
(Date:3/29/2017)... ... March 29, 2017 , ... Based ... into the challenges employers face in trying to balance both short-term and long-term ... programs? Adding to the growing complexity, companies are finding that the short-term ...
(Date:3/29/2017)... (PRWEB) , ... March 29, 2017 , ... ... Device Library for documenting and diagramming network and data center assets and audio-video ... NetZoom subscribers can request new equipment shapes for free and download shapes and ...
Breaking Medicine News(10 mins):